Ind-Swift Laboratories Ltd

Ind-Swift Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ind-Swift Laboratories Ltd

₹ 119 1.76%
19 Apr - close price
indswiftlabs.com BSE: 532305 NSE : INDSWFTLAB
About

Incorporated in 1995, Ind-Swift Laboratories Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients(APIs), and Advanced Intermediates, and providing Contract Research and Manufacturing Services (CRAMS). [1]

Key Points

Business Segments
APIs: The Co. manufactures APIs for complex therapies including Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, etc. [1]
CRAMS: The Co. provides Contract Research and Manufacturing Services supporting R&D programs from process development to clinical supplies. Its capabilities include synthetic medicinal chemistry, custom synthesis, process R&D, cGMP manufacturing, analytical development, and regulatory support. [2]
Research & Development: The Co. has an R&D center primarily focused on the development and optimization of new and existing process technologies supporting the manufacturing of APIs. [2]
Impurities: The Co. has impurities for over 25 APIs. The Co’s impurity portfolio is stocked with a wide range of standards for quick and reliable supply. [3]

Website BSE NSE
  • Market Cap ₹ 701 Cr.
  • Current Price ₹ 119
  • High / Low ₹ 138 / 63.0
  • Stock P/E 28.0
  • Book Value ₹ 122
  • Dividend Yield 0.00 %
  • ROCE 12.8 %
  • ROE 8.54 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.97 times its book value
  • Company has delivered good profit growth of 24.3% CAGR over last 5 years

Cons

  • Company has a low return on equity of 2.53% over last 3 years.
  • Promoters have pledged 86.8% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
221 218 242 230 240 276 272 288 302 290 299 270 276
173 177 191 175 187 241 219 231 246 234 239 207 222
Operating Profit 48 41 51 55 53 35 53 57 56 56 60 63 54
OPM % 22% 19% 21% 24% 22% 13% 20% 20% 18% 19% 20% 23% 20%
6 3 6 7 6 21 7 8 8 -17 6 7 7
Interest 25 24 24 24 24 23 24 24 22 22 20 21 21
Depreciation 20 28 14 14 21 82 16 16 15 9 14 13 14
Profit before tax 9 -8 19 24 15 -50 20 24 26 9 31 36 27
Tax % 0% -241% 0% 0% 0% -27% 0% 0% -10% 461% 45% 17% 19%
9 -29 19 24 15 -63 20 24 29 -31 17 30 22
EPS in Rs 1.56 -4.91 3.17 4.04 2.52 -10.69 3.41 4.07 4.95 -5.23 2.89 5.09 3.66
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,321 1,081 941 646 639 694 731 724 752 857 988 1,152 1,136
1,145 1,011 882 557 532 589 604 599 610 676 788 930 902
Operating Profit 176 70 59 89 107 105 127 125 142 180 200 222 234
OPM % 13% 7% 6% 14% 17% 15% 17% 17% 19% 21% 20% 19% 21%
32 4 -19 -31 1 15 16 130 36 23 34 7 3
Interest 85 140 117 117 106 88 28 92 107 100 96 92 84
Depreciation 40 54 66 84 85 88 87 104 90 87 131 57 50
Profit before tax 83 -120 -143 -143 -83 -56 29 59 -20 16 8 79 103
Tax % -4% 1% 14% 17% 29% 29% 38% 35% -6% 127% 171% 46%
86 -119 -123 -119 -59 -40 18 39 -21 -4 -6 42 38
EPS in Rs 22.78 -30.30 -29.96 -29.09 -14.37 -8.88 3.89 8.11 -3.52 -0.74 -0.97 7.19 6.41
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 1%
5 Years: 10%
3 Years: 15%
TTM: 0%
Compounded Profit Growth
10 Years: 10%
5 Years: 24%
3 Years: 67%
TTM: 146%
Stock Price CAGR
10 Years: 12%
5 Years: 26%
3 Years: 16%
1 Year: 80%
Return on Equity
10 Years: -4%
5 Years: 0%
3 Years: 3%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 38 39 41 42 42 45 46 48 60 60 60 60 60
Reserves 783 813 682 551 473 480 497 542 585 579 573 616 662
1,013 1,240 1,355 1,413 1,457 1,242 1,083 1,148 1,031 996 944 854 793
371 272 252 233 238 353 371 174 184 182 226 259 237
Total Liabilities 2,205 2,364 2,330 2,238 2,210 2,121 1,997 1,913 1,860 1,817 1,803 1,788 1,752
909 1,169 1,173 1,114 1,095 1,042 934 913 843 752 630 587 570
CWIP 294 161 78 115 82 70 69 20 11 19 10 8 8
Investments 29 27 27 26 26 26 26 26 26 55 111 85 85
973 1,006 1,052 983 1,007 982 968 953 979 991 1,052 1,108 1,089
Total Assets 2,205 2,364 2,330 2,238 2,210 2,121 1,997 1,913 1,860 1,817 1,803 1,788 1,752

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
76 -46 0 100 80 93 71 -75 123 135 136 183
-204 -48 0 -37 -30 -31 -17 -2 -10 -10 3 -14
125 66 0 -64 -48 -69 -62 100 -133 -124 -140 -168
Net Cash Flow -2 -28 0 -0 3 -7 -8 23 -20 1 -1 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 78 133 166 212 205 179 191 168 187 171 158 149
Inventory Days 173 190 187 319 377 317 305 302 330 304 303 253
Days Payable 84 81 102 119 137 88 112 110 122 106 120 114
Cash Conversion Cycle 168 242 250 412 445 409 384 359 395 368 342 287
Working Capital Days 171 255 279 287 253 108 97 317 324 294 288 261
ROCE % 10% 2% 0% 1% 2% 2% 3% 4% 5% 7% 7% 13%

Shareholding Pattern

Numbers in percentages

56 Recently
Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
42.00% 42.00% 42.00% 42.00% 42.00% 42.00% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01%
0.17% 0.05% 0.01% 0.22% 0.06% 0.00% 0.00% 0.04% 0.00% 0.08% 0.17% 0.31%
19.49% 19.50% 19.49% 19.50% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 18.73%
38.34% 38.46% 38.50% 38.29% 38.44% 38.50% 38.51% 38.48% 38.52% 38.44% 38.34% 38.96%
No. of Shareholders 15,85921,46625,22524,52825,34224,91024,22624,45623,39722,96225,40524,633

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT